CD8A and neoplasm: Oxaliplatin was given ip at 10 mg/kg, a dose that has been shown to be tolerated and to exhibit cytotoxic activity against tumors.15 During tumor progression, percentages of CD8+ T cells, CD4+ T cells, and FoxP3+ Tregs were reduced in the spleen, while their absolute numbers were increased, though this difference was not significant (Figure 1A‐C).